Publications by authors named "G F Carvalhal"
Introduction: Levothyroxine (L-T4) monotherapy is the standard of care for the treatment of hypothyroidism. A minority of the L-T4-treated patients remain symptomatic and report better outcomes with combination therapy that contains liothyronine (L-T3) or with desiccated thyroid extract (DTE).
Goal: To assess patient preferences in the treatment of hypothyroidism.
The Thr92Ala polymorphism in the type 2 deiodinase gene is linked to depression in patients with COVID-19 after hospital discharge.
Front Endocrinol (Lausanne)
June 2024
Article Synopsis
- The Thr92Ala-DIO2 polymorphism was studied for its impact on depressive symptoms in patients who had moderate to severe COVID-19.
- A cohort of 273 hospitalized patients was assessed, with post-discharge follow-ups conducted on 68 patients categorized by their depressive status.
- Results indicated that patients with the Thr/Ala genotype had a significantly lower incidence of depressive symptoms compared to those with Thr/Thr or Ala/Ala genotypes, suggesting a potential protective effect against post-COVID-19 depression.
Introduction: The type 2 deiodinase and its Thr92Ala-DIO2 polymorphism have been linked to clinical outcomes in acute lung injury and coronavirus disease 2019 (COVID-19).
Objective: The objective was to identify a potential association between Thr92Ala-DIO2 polymorphism and body composition (appendicular muscle mass, myosteatosis, and fat distribution) and to determine whether they reflect the severity or mortality associated with the disease.
Methods: In this prospective cohort study (June-August 2020), 181 patients hospitalized with moderate-to-severe COVID-19 underwent a non-contrast-enhanced computed tomography (CT) of the thorax to assess body composition, laboratory tests, and genotyping for the Thr92Ala-DIO2 polymorphism.
Objective: The objective of this narrative review is to discuss the current state of research funding in Brazil.
Materials And Methods: This study is based on the most recent edition of the course Funding for Research and Innovation in the University of Sao Paulo School of Medicine which was a three-day course with 12 hours of instruction. The course brought together leading experts in the field to comprehensively discuss the current state of research funding in Brazil.